Borregaard reported Q2 2026 operating revenues of NOK 2,114 million (vs. NOK 2,045 million), a +3.4% increase. EBITDA was NOK 515 million versus NOK 522 million (-1.3%), with BioMaterials and Fine Chemicals improving while BioSolutions declined versus Q2 2025. Net effect is mixed (slightly softer profitability despite higher revenue).
Borregaard reported Q2 2026 operating revenues of NOK 2,114 million (vs. NOK 2,045 million), a +3.4% increase. EBITDA was NOK 515 million versus NOK 522 million (-1.3%), with BioMaterials and Fine Chemicals improving while BioSolutions declined versus Q2 2025. Net effect is mixed (slightly softer profitability despite higher revenue).
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
neutral
Sentiment Score
-0.05
Ticker Sentiment
